Fmr LLC Has $37.54 Million Stake in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

FMR LLC lessened its holdings in Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) by 11.9% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 18,678,527 shares of the company's stock after selling 2,532,109 shares during the quarter. FMR LLC owned 9.11% of Taysha Gene Therapies worth $37,544,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of TSHA. Creative Planning acquired a new stake in shares of Taysha Gene Therapies during the 3rd quarter valued at $28,000. Principal Financial Group Inc. bought a new position in Taysha Gene Therapies during the 2nd quarter worth $48,000. China Universal Asset Management Co. Ltd. raised its position in Taysha Gene Therapies by 79.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 39,417 shares of the company's stock worth $79,000 after purchasing an additional 17,446 shares during the last quarter. Intech Investment Management LLC bought a new position in Taysha Gene Therapies during the 3rd quarter worth $85,000. Finally, Scientech Research LLC bought a new position in Taysha Gene Therapies during the 2nd quarter worth $97,000. Institutional investors and hedge funds own 77.70% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on TSHA shares. Chardan Capital reissued a "buy" rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a research report on Thursday, November 14th. Cantor Fitzgerald reissued an "overweight" rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Canaccord Genuity Group lifted their price objective on Taysha Gene Therapies from $6.00 to $8.00 and gave the stock a "buy" rating in a research report on Friday, November 15th. Needham & Company LLC reissued a "buy" rating and issued a $6.00 price objective on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Finally, JMP Securities reissued a "market outperform" rating and issued a $5.00 price objective on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $6.63.

Taysha Gene Therapies Stock Up 3.2 %

Shares of TSHA traded up $0.08 during trading hours on Monday, hitting $2.56. The stock had a trading volume of 1,888,835 shares, compared to its average volume of 2,831,645. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.51 and a quick ratio of 5.51. The firm has a 50 day simple moving average of $2.11 and a 200-day simple moving average of $2.38. The firm has a market capitalization of $524.65 million, a P/E ratio of 4.06 and a beta of 0.79. Taysha Gene Therapies, Inc. has a 1-year low of $1.19 and a 1-year high of $4.32.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.